Teva Australia

A 2015 report by Sum Of Us reveals that the largest pharmaceutical corporations are complicit in fuelling one of the most serious public health crises facing society today. Pharmaceutical companies, including this one, are sourcing active pharmaceutical ingredients (APIs) from companies in China which are responsible for massive environmental pollution from its antibiotic factories. Teva has links with at least three of the Chinese companies identified in the report, all of which have been in the Chinese media spotlight for various offences including improper waste management and the release of noxious chemicals.
Source: Changing Markets (2015)

In 2016 this company agreed to pay more than $519 million to settle US criminal and civil allegations that the company bribed officials in Mexico, Russia and Ukraine to gain business for its medications. [Listed under Information due to age of court finding]
Source: news article (2016)

In 2015 this company agreed to pay US$1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. The settlement stems from charges brought in 2008 against Cephalon Inc, which was acquired by Teva in 2012.
Source: news article (2015)

This company has products that are certified by the Carbon Trust, signifying that the carbon footprint of selected products has been measured, managed and reduced. A life cycle product carbon footprint is determined by calculating the total greenhouse gas emissions generated by a product, from extraction of raw-materials, to end-of-life.
Source: Carbon Trust (2021)

As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target.
Source: We Mean Business (2021)

This company has Responsibility claims on its website.
Source: company website (2018)

This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)

The 2021 Antimicrobial Resistance (AMR) Benchmark ranks 17 large pharmaceutical companies on their efforts keep medicines and vaccines available, despite the rise of drug resistance. This company received a score of 60%.
Source: Access to Medicine Foundation (2021)

This company received an S&P Global ESG Score of 54/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 16 Dec 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2022)